Gut bacteria and immunotherapy for advanced colon cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for advanced colorectal cancer that has spread. It aims to find out if certain gut bacteria can help make treatment more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic)
- You are between 35 and 75 years old
- Your full medical records are available for review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study looks at how gut bacteria (the microbiome) change during treatment for colorectal cancer that has spread or cannot be removed. Researchers hope the findings may help improve understanding of how treatment works and how to tailor care.
Hear when a new Colorectal Neoplasms Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.